Kerry Beth’s expertise spans corporate reputation, product strategy, internal and executive communications, and communications measurement. While at Amgen, she led the communications for three business units/therapeutic areas that were crucial to the Company’s valuation and reputation. She also worked to create and amplify the Company’s pipeline story among key financial, policy, payer, medical, and consumer stakeholders.
Prior to joining Amgen, Kerry Beth was an executive at Fleishman-Hillard, a global communications, brand marketing, and digital firm. There, she created and built the Company’s life sciences practice in two key markets, addressing scalable staffing, organizational design, culture, business development, branding, financial planning, and team training and professional development. She managed flagship accounts such as Genentech, Pfizer, and Roche helping build product and corporate brands, addressing crisis scenarios, and leveraging or mitigating industry trends.
Kerry Beth holds a B.S. in communications from The S.I. Newhouse School of Public Communications and a B.A. in public policy and sociology from The Maxwell School of Citizenship and Public Affairs, both at Syracuse University.